Loading...

Home
ETF
CANF

CANF

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

CANF News

Can-Fite Biopharma Reports FY 2025 Financial Results

5d agoseekingalpha

Can-Fite BioPharma Reports 2025 Financial Results and Clinical Advances

5d agoNewsfilter

CAN-FITE ANNOUNCES 2025 FINANCIAL RESULTS AND CLINICAL ADVANCEMENTS, SHOWCASING PROMISING PHASE 2A DATA FOR PANCREATIC CANCER AND NINE-YEAR CANCER-FREE SURVIVAL IN LIVER CANCER PATIENTS

Can-Fite BioPharma's Drug Trial Achieves Success

Mar 04 2026NASDAQ.COM

Can-Fite BioPharma's Drug Trial Success Boosts Shares

Mar 04 2026Benzinga

Can-Fite BioPharma Completes Financing Agreement

Mar 04 2026Newsfilter

U.S. Stocks Rise in Morning Trading, Dow Jones Up Over 100 Points

Mar 04 2026Benzinga

Can-Fite BioPharma Shares Surge 40% on Positive Trial Results

Mar 04 2026stocktwits

UiPath to Join S&P Midcap 400 Index Effective January 2, 2026

Dec 27 2025Yahoo Finance

Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split, Shares Plunge 38.4%

Dec 26 2025Benzinga

Can-Fite BioPharma Secures Patent in Brazil for A3AR Agonist in Sexual Dysfunction Treatment

Dec 26 2025NASDAQ.COM

Can-Fite Secures Brazilian Patent for Sexual Dysfunction Drug

Dec 26 2025Globenewswire

Can-Fite Secures Brazilian Patent for A3AR Agonist in Sexual Dysfunction Treatment

Dec 26 2025Newsfilter

Multi Ways Holdings Reports 87.65% Revenue Growth to $26.44 Million in H1 2025

Dec 24 2025Benzinga

UiPath to Replace Synovus in S&P MidCap 400 Effective January 2, 2026

Dec 24 2025Benzinga

Can-Fite BioPharma Approves 1-for-3,000 Reverse Split Following Shareholder Approval

Dec 23 2025Globenewswire